ClinicalTrials.gg
RecruitingNCT06396416Updated Jun 29, 2026

Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

A Phase 4 interventional study of Semaglutide and Virtual Weight Management Coaching in Obesity and Chronic Kidney Disease, sponsored by Western University, Canada. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Western University, Canada · Phase 4, Interventional, and Other

How we know · 4 judgments

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 145 studies testing semaglutide in Obesity — 70 open to participants now, 79 under way, 15 of them phase 3. Semaglutide · Obesity.

Planned enrollment
101st of 145
60 · median 100
Started
2024
with 18 others
Phase 4
40 of 145
20 open now
Primary completion
2026-09
later than 15 of 78 live
Registered
75th of 145
by date

Among the 145 studies testing semaglutide in Obesity, this one is the 101st largest by planned enrollment, is one of 19 that started in 2024, is one of 40 in phase 4, reaches primary completion later than 15 of the 78 other live ones, and was the 75th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

70 of the 145 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

65 more — sign in →

By country, each count listing its studies:

All 70 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial.

We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.

Read the detailed description

Obesity is well-recognized as an independent risk factor for chronic kidney disease (CKD) including end-staged kidney disease (ESKD). In people with ESKD, obesity can preclude access to lifesaving kidney transplantation. Of solid organ transplant programs in Canada, 80% exclude people with obesity (based upon body mass index or BMI), due to a potential risk of perioperative complications and post-transplant mortality.

Losing weight for kidney transplantation can, however, be extremely difficult. Medications that can promote weight loss in other populations including glucagon-like peptide 1 receptor agonists (GLP-1RA; liraglutide, semaglutide, and dulaglutide) and glucose-dependent insulinotropic polypeptide (GIP-1RA)/GLP-1RAs (tirzepatide), have not been studied in devoted trials of advanced CKD participants, and their efficacy and safety remain unclear.

Nutritional advice is often very difficult to follow when trying to balance kidney and diabetes diets (e.g. potassium), and if diets are too restrictive, there may be protein-energy wasting which could be detrimental to patients. People with high-risk CKD frequently live with functional impairment which can limit exercise. Weight loss programs can be cost prohibitive to those who are already socioeconomically disadvantaged.

A vanguard is needed before a large, multicentered RCT: A feasibility study will allow us to ensure that we can recruit a sufficient sample of participants into our trial, that our trial processes are inclusive, and that they are acceptable to patients. In the vanguard phase of our trial, we will answer the following questions:

  1. Is participant recruitment into a large multi-centered trial feasible?
  2. Will participants remain adherent to their assigned treatment arm over 26 weeks of study?
  3. Will participants find our program acceptable?
  4. Will safety events preclude us from testing our intervention in a larger RCT?
03

Conditions studied

  • Obesity
  • Chronic Kidney Disease

Keywords

  • Weight Management
  • Transplant
  • GLP-1RA
  • Pilot Study
  • Registries
  • Pragmatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older
  • ; 35 kg/m\^2
  • 10% risk of ESKD requiring renal replacement therapy over 2 years or receiving dialysis

Exclusion criteria

Exclusion Criteria:

  • Known to a GLP-1RA (pancreatitis, personal or family history of medullary thyroid cancer, )
  • Type 1 diabetes
  • No access to semaglutide via drug coverage
  • Pregnant, breastfeeding or planning to become pregnant
  • Currently in a GLP-1RA or GLP-1RA/GIP study or planning to be in one
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Virtual Weight Management Program

    A maximum tolerated dose of semaglutide (Ozempic/Wegovy) will be administered once weekly subcutaneously, up to a dose of 2.0 mg. Participants will also receive nutritional and movement advice, as well as virtual coaching once every 4 weeks for 6 months.

    Drug: Semaglutide · Behavioral: Virtual Weight Management Coaching

  • No intervention
    Usual Care

    Usual care participants will continue to receive the typical standard of kidney and diabetes care. They will not receive any study medication or coaching.

Interventions

  • Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.

    Also known as: GLP-1RA, Ozempic, Wegovy

  • BehavioralVirtual Weight Management Coaching

    Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.

06

What researchers measure

Primary outcomes

  1. Feasibility of Recruitment

    Number of participants enrolled across three centers, with success defined as recruitment of ≥ 60 participants within the 12-month enrollment period.

    Time frame: 12 months

Secondary outcomes

  1. Adherence to Scheduled Coaching Visits

    Percentage of participants randomized to the intervention attend \>75% of their scheduled coaching visits.

    Time frame: 12 months

  2. Adherence to GLP-1RA Therapy

    Percentage of participants randomized to the intervention fill \>75% of their semaglutide prescriptions.

    Time frame: 12 months

  3. Recruitment of ≥20 Participants in First 12 Weeks

    Recruitment of ≥20 participants in first 12 Weeks of trial initiation

    Time frame: First 12 weeks

  4. Recruitment Per Site Within 12 Weeks

    At least one participant recruited per site within 12 weeks of trial initiation each active site

    Time frame: First 12 weeks

  5. Incidence of Acute Kidney Injury

    Number of participants experiencing acute kidney injury (AKI)

    Time frame: 12 months

  6. Incidence of Hypoglycemia

    Number of participants experiencing hypoglycemia

    Time frame: 12 months

  7. Incidence of Gastrointestinal Side Effects

    Number of participants experiencing GI side effects

    Time frame: 12 months

  8. Change in Dalhousie Clinical Frailty Scale Classification

    Change in participant's Dalhousie Clinical Frailty Scale Classification from baseline to 26 weeks. The scale has 9 options, from 1 (very fit) to 9 (terminally ill).

    Time frame: 26 weeks

  9. Change in SARC-F Score of Sarcopenia

    Change in participant's SARC-F questionnaire score from baseline to 26 weeks. Out of 8 points, a SARC-F score of ≥4 best predicts the need for further, more comprehensive clinical evaluation.

    Time frame: 26 weeks

  10. Change in Body Weight - Smart Scale

    Change in weight from baseline to 26 weeks, measured in kilograms. Measured using a Smart Scale in a subpopulation.

    Time frame: 26 weeks

  11. Change in Body Fat - Smart Scale

    Change in body fat from baseline to 26 weeks, measured in percentage. Measured using Smart Scale in subpopulation.

    Time frame: 26 weeks

  12. Change in Muscle Mass - Smart Scale

    Change in muscle mass from baseline to 26 weeks. Measured in kilograms. Measured using Smart Scale in subpopulation.

    Time frame: 26 weeks

  13. Change in Body Water Content - Smart Scale

    Change in body water content from baseline to 26 weeks. Measured in percentage. Measured using Smart Scale in subpopulation.

    Time frame: 26 weeks

  14. In-Clinic Height Measurement

    In-clinic height measurements, measured in centimeters

    Time frame: Baseline, 3 months, 6 months

  15. In-Clinic Weight Measurement

    In-clinic weight measurements, measured in kilograms

    Time frame: Baseline, 3 months, 6 months

  16. In-Clinic Body Mass Index Measurement

    In-clinic BMI measurements, measured in kg/m\^2

    Time frame: Baseline, 3 months, 6 months

Other outcomes

  1. Percentage of Change in HbA1c

    Percentage of change in HbA1c from baseline to 26 weeks, measured in percentage

    Time frame: 26 weeks

  2. Change in 2-week glycemic variability

    For those using a Libre or Continuous Glucose Monitoring at baseline, Percentage of change in 2-week glycemic variability from baseline to 26 weeks

    Time frame: 26 weeks

  3. Change in Time-in-Range

    For those using a Libre or Continuous Glucose Monitoring at baseline, Percentage of change in Time-in-Range from baseline to 26 weeks

    Time frame: 26 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Demographics (age, sex, etc.) Baseline characteristics Lab Values Outcome Measurements Adverse event data Other data points collected for each participant

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning immediately following publication; no end date

Access criteria: De-identified individual participant data will be made available to qualified researchers who provide a methodologically sound research proposal. Requests will be reviewed by the study investigators. Data will be provided following execution of an appropriate data use agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 24 months is below that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 2, 2024
StartActual
Sep 26, 2024
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06396416
Responsible party
Kristin Clemens (Associate Professor, Western University, Canada) — Principal investigator
First posted
May 2, 2024
Start date
Sep 26, 2024
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 29, 2026

Study contacts

Heather LaPier, BSc
Contact
heather.lapier@sjhc.london.on.ca
519-646-6100 ext. 65373
Kristin K Clemens, MD, MSc
principal investigator · St. Joseph's Health Care London
Louise Moist, MD, MSc
principal investigator · London Health Sciences Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion